After filing its first ANDA in US in 2003, it has come a long way as current ANDA filings are at 629. US revenues have grown from ~US$100 million in 2009 crossing $1.6 billion sales as on 2020. In rupee terms, US sales have grown at 17% CAGR to | 11484 crore in FY16-20. US formulations now comprise 50% of turnover, up from 30% in FY13. Despite calling off acquisition of Sandoz' US dermatology, oral solid portfolio, sale of Natrol business, we expect US revenue to reach | 13661 crore in FY23E at 6% CAGR...